131 related articles for article (PubMed ID: 11939309)
1. Finasteride-induced prostatic involution by apoptosis in dogs with benign prostatic hypertrophy.
Sirinarumitr K; Sirinarumitr T; Johnston SD; Sarkar DK; Kustritz MV
Am J Vet Res; 2002 Apr; 63(4):495-8. PubMed ID: 11939309
[TBL] [Abstract][Full Text] [Related]
2. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy.
Sirinarumitr K; Johnston SD; Kustritz MV; Johnston GR; Sarkar DK; Memon MA
J Am Vet Med Assoc; 2001 Apr; 218(8):1275-80. PubMed ID: 11330612
[TBL] [Abstract][Full Text] [Related]
3. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
4. Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs.
Angrimani DSR; Silvestrini GR; Brito MM; Abreu RA; Almeida LL; Vannucchi CI
Theriogenology; 2018 Jul; 114():103-108. PubMed ID: 29605575
[TBL] [Abstract][Full Text] [Related]
5. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
Glassman DT; Chon JK; Borkowski A; Jacobs SC; Kyprianou N
Prostate; 2001 Jan; 46(1):45-51. PubMed ID: 11170131
[TBL] [Abstract][Full Text] [Related]
6. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride.
Golchin-Rad K; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Derakhshandeh N; Abbaszadeh-Hasiri M
Top Companion Anim Med; 2020 Mar; 38():100405. PubMed ID: 32115076
[TBL] [Abstract][Full Text] [Related]
7. Reproductive and endocrinological effects of Benign Prostatic Hyperplasia and finasteride therapy in dogs.
Angrimani DSR; Brito MM; Rui BR; Nichi M; Vannucchi CI
Sci Rep; 2020 Sep; 10(1):14834. PubMed ID: 32908208
[TBL] [Abstract][Full Text] [Related]
8. Endocrine, prostatic vascular, and proapoptotic changes in dogs with benign prostatic hyperplasia treated medically or surgically.
Lima CB; Angrimani DSR; Flores RB; Vannucchi CI
Domest Anim Endocrinol; 2021 Apr; 75():106601. PubMed ID: 33333452
[TBL] [Abstract][Full Text] [Related]
9. Blood dripping from the penis of a German Shepherd dog.
Sontas BH; Milani C; Mollo A; Romagnoli S
Aust Vet J; 2010 Jun; 88(6):242-4. PubMed ID: 20553576
[No Abstract] [Full Text] [Related]
10. Questions whether clients were properly informed about treatment protocol.
Koltveit AJ
J Am Vet Med Assoc; 2001 Jun; 218(11):1721-2. PubMed ID: 11394816
[No Abstract] [Full Text] [Related]
11. Effect of finasteride (Proscar MSD) on seminal composition, prostate function and fertility in male dogs.
Iguer-Ouada M; Verstegen JP
J Reprod Fertil Suppl; 1997; 51():139-49. PubMed ID: 9404280
[TBL] [Abstract][Full Text] [Related]
12. Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia.
Bozec A; Ruffion A; Decaussin M; Andre J; Devonec M; Benahmed M; Mauduit C
J Clin Endocrinol Metab; 2005 Jan; 90(1):17-25. PubMed ID: 15507514
[TBL] [Abstract][Full Text] [Related]
13. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
[TBL] [Abstract][Full Text] [Related]
14. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
Sutton MT; Yingling M; Vyas A; Atiemo H; Borkowski A; Jacobs SC; Kyprianou N
Prostate; 2006 Aug; 66(11):1194-202. PubMed ID: 16652387
[TBL] [Abstract][Full Text] [Related]
15. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride.
Sáez C; González-Baena AC; Japón MA; Giráldez J; Segura DI; Rodríguez-Vallejo JM; González-Esteban J; Miranda G; Torrubia F
Prostate; 1999 Jul; 40(2):83-8. PubMed ID: 10386468
[TBL] [Abstract][Full Text] [Related]
16. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia.
Hochberg DA; Basillote JB; Armenakas NA; Vasovic L; Shevchuk M; Pareek G; Fracchia JA
J Urol; 2002 Apr; 167(4):1731-3. PubMed ID: 11912398
[TBL] [Abstract][Full Text] [Related]
17. Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy.
Angrimani DSR; Francischini MCP; Brito MM; Vannucchi CI
PLoS One; 2020; 15(6):e0234714. PubMed ID: 32584842
[TBL] [Abstract][Full Text] [Related]
18. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB
J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609
[TBL] [Abstract][Full Text] [Related]
19. Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5 .
Thomas LN; Wright AS; Lazier CB; Cohen P; Rittmaster RS
Prostate; 2000 Feb; 42(3):203-10. PubMed ID: 10639191
[TBL] [Abstract][Full Text] [Related]
20. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
Granados Loarca EA
Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
